PHARMA PCT/ON-CYCLE SUPPORT

Sort By:  
Click image to see product details
$50.00
Click image to see product details
$60.00
Choose option to see price
$0.00
Click image to see product details
$20.00
Click image to see product details
$30.00
Click image to see product details
$50.00
Click image to see product details
$70.00
Choose option to see price
$0.00
Click image to see product details
$25.00
Choose option to see price
$0.00
Choose option to see price
$0.00
ARIMIDEX
1MG/TAB * 28TAB

Pharmacology
Anastrozole is a potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels.

Absorption
Well absorbed; extent of absorption not affected by food.

Metabolism
Extensively hepatic (~85%) via N-dealkylation, hydroxylation, and glucuronidation; primary metabolite (triazole) inactive.

Time to Peak
Plasma: ~2 hours without food; 5 hours with food.

Half-Life Elimination
~50 hours.

Detection Time
~14 days.


Click image to see product details
$50.00
AROMASIN

25MG/TAB * 30TAB

Pharmacology
Exemestane is an irreversible, steroidal aromatase inactivator. It is structurally related to androstenedione, and is converted to an intermediate that irreversibly blocks the active site of the aromatase enzyme, leading to inactivation ("suicide inhibition") and thus preventing conversion of androgens to estrogens in peripheral tissues. Significantly lowers circulating estrogens in postmenopausal breast cancers where growth is estrogen-dependent.


Absorption
Rapid and moderate (~42%) following oral administration; AUC and Cmax increased by 59% and 39%, respectively, following a high-fat breakfast (compared to fasted state).


Metabolism
Extensively hepatic; oxidation (CYP3A4) of methylene group, reduction of 17-keto group with formation of many secondary metabolites; metabolites are inactive.


Time to Peak
1.2 hours.


Half-Life Elimination
~24 hours.


Detection Time
~14 days.

Click image to see product details
$60.00
ARVEKAP
7 VIALS x 0,1 MG + 7 AMPS x 1 ML / 1 VIAL x 3,75MG/VIAL + 1 AMP
Choose option to see price
$0.00
CLOMIPHENE
50MG/TAB * 24TAB

Pharmacology
Clomiphene is a racemic mixture consisting of zuclomiphene (~38%) and enclomiphene (~62%), each with distinct pharmacologic properties. Clomiphene acts at the level of the hypothalamus, occupying cell surface and intracellular estrogen receptors (ERs) for longer durations than estrogen. This interferes with receptor recycling, effectively depleting hypothalamic ERs and inhibiting normal estrogenic negative feedback. Impairment of the feedback signal results in increased pulsatile GnRH secretion from the hypothalamus and subsequent pituitary gonadotropin (FSH, LH) release, causing growth of the ovarian follicle, followed by follicular rupture (ASRM 2013; Dickey, 1996).

Absorption
Readily absorbed.


Metabolism
Hepatic; undergoes enterohepatic recirculation (Goldstein 2000).


Time to Peak
~6 hours (Goldstein 2000).


Half-Life Elimination
~5 days (Goldstein 2000).


Detection Time
~60 days.

Click image to see product details
$20.00
DOSTINEX
0,5MG/TAB - 8TABS
$40.00
EVISTA
60MG/TAB * 28TAB

Pharmacology
Raloxifene is an estrogen agonist/antagonist (a selective estrogen receptor modulator [SERM]); selective binding activates estrogenic pathways in some tissues and antagonizes estrogenic pathways in other tissues. Raloxifene acts like an estrogen agonist in the bone to prevent bone loss and has estrogen antagonist activity to block some estrogen effects in the breast and uterine tissues. Raloxifene decreases bone resorption, increasing bone mineral density and decreasing fracture incidence.

Absorption
Rapid; ~60%


Metabolism
Hepatic, extensive first-pass metabolism; metabolized to glucuronide conjugates.


Half-Life Elimination
27.7 hours (following a single dose); 32.5 hours (following multiple doses).

Click image to see product details
$30.00
EXEMESTANE

25MG/TAB * 30TAB



Pharmacology
Exemestane is an irreversible, steroidal aromatase inactivator. It is structurally related to androstenedione, and is converted to an intermediate that irreversibly blocks the active site of the aromatase enzyme, leading to inactivation ("suicide inhibition") and thus preventing conversion of androgens to estrogens in peripheral tissues. Significantly lowers circulating estrogens in postmenopausal breast cancers where growth is estrogen-dependent.


Absorption
Rapid and moderate (~42%) following oral administration; AUC and Cmax increased by 59% and 39%, respectively, following a high-fat breakfast (compared to fasted state).


Metabolism
Extensively hepatic; oxidation (CYP3A4) of methylene group, reduction of 17-keto group with formation of many secondary metabolites; metabolites are inactive.


Time to Peak
1.2 hours.


Half-Life Elimination
~24 hours.


Detection Time
~14 days.


Click image to see product details
$50.00
FEMARA
2,5MG/TAB * 30TAB


Pharmacology
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system which binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgens to estrogens (specifically, androstenedione to estrone and testosterone to estradiol). This leads to inhibition of the enzyme and a significant reduction in plasma estrogen (estrone, estradiol and estrone sulfate) levels. Does not affect synthesis of adrenal or thyroid hormones, aldosterone, or androgens.

Absorption
Rapid and well absorbed; not affected by food.

Metabolism
Hepatic via CYP3A4 and 2A6 to an inactive carbinol metabolite.

Time to Peak
Steady state, plasma: 2 to 6 weeks; steady state serum concentrations are 1.5 to 2 times higher than single-dose values.

Half-Life Elimination
Terminal: ~2 days.

Detection Time
~14 days.


Click image to see product details
$70.00
NOLVADEX, Rx
10MG/TAB * 100TAB - 20MG/TAB * 100TAB

Pharmacology
Tamoxifen competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G0 and G1 phases; therefore, tamoxifen is cytostatic rather than cytocidal.

Absorption
Well absorbed.


Metabolism
Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen.


Time to Peak
Serum: ~5 hours.


Half-Life Elimination
Tamoxifen: ~5 to 7 days; N-desmethyl tamoxifen: ~14 days


Detection Time
~60 days.

Choose option to see price
$0.00
NOLVADEX-D
20MG/TAB * 30TAB

Pharmacology
Tamoxifen competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G0 and G1 phases; therefore, tamoxifen is cytostatic rather than cytocidal.

Absorption
Well absorbed.


Metabolism
Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen.


Time to Peak
Serum: ~5 hours.


Half-Life Elimination
Tamoxifen: ~5 to 7 days; N-desmethyl tamoxifen: ~14 days


Detection Time
~60 days.

Click image to see product details
$25.00
PARLODEL
30CAP * 2.5MG/CAP - 30CAP * 5MG/CAP - 30CAP * 10MG/CAP
Choose option to see price
$0.00
PRAMIPEXOLE
0,18MG/TAB - 30/100TABS
Choose option to see price
$0.00
Per Page      1 - 12 of 12
  • 1